Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients
- 15 July 2010
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 84 (14), 6935-6942
- https://doi.org/10.1128/jvi.00453-10
Abstract
Ibalizumab is a humanized monoclonal antibody that binds human CD4, the primary receptor for human immunodeficiency virus type 1 (HIV-1). With its unique specificity for domain 2 of CD4, this antibody potently and broadly blocks HIV-1 infection in vitro by inhibiting a postbinding step required for viral entry but without interfering with major histocompatibility complex class II (MHC-II)-mediated immune function. In clinical trials, ibalizumab has demonstrated anti-HIV-1 activity in patients without causing immunosuppression. Thus, a characterization of the ibalizumab epitope was conducted in an attempt to gain insight into the underlying mechanism of its antiviral activity as well as its safety profile. By studying mouse/human chimeric CD4 molecules and site-directed point mutants of CD4, amino acids L96, P121, P122, and Q163 in domain 2 were found to be important for ibalizumab binding, with E77 and S79 in domain 1 also contributing. All these residues appear to cluster on the interface between domains 1 and 2 of human CD4 on a surface opposite the site where gp120 and the MHC-II molecule bind on domain 1. Separately, the epitope of M-T441, a weakly neutralizing mouse monoclonal antibody that competes with ibalizumab, was localized entirely within domain 2 on residues 123 to 125 and 138 to 140. The results reported herein not only provide an appreciation for why ibalizumab has not had significant adverse immunological consequences in infected patients to date but also raise possible steric hindrance mechanisms by which this antibody blocks HIV-1 entry into a CD4-positive cell.This publication has 37 references indexed in Scilit:
- Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected AdultsAntimicrobial Agents and Chemotherapy, 2009
- Challenges in the development of an HIV-1 vaccineNature, 2008
- Molecular architecture of native HIV-1 gp120 trimersNature, 2008
- Synergistic In Vitro Antiretroviral Activity of a Humanized Monoclonal Anti-CD4 Antibody (TNX-355) and Enfuvirtide (T-20)Antimicrobial Agents and Chemotherapy, 2006
- Antibody neutralization and escape by HIV-1Nature, 2003
- CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5Nature, 1996
- In VivoAdministration to Rhesus Monkeys of a CD4-Specific Monoclonal Antibody Capable of Blocking AIDS Virus ReplicationAIDS Research and Human Retroviruses, 1993
- Crystal structure of an HIV-binding recombinant fragment of human CD4Nature, 1990
- The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brainCell, 1986
- The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirusNature, 1984